In the field of neurology, IVIg has a dramatic impact in the treatment of autoimmune disorders, with a significant improvement in the quality of life of patients. The success of IVIg therapy has meant that it is being used in an ever increasing number of disorders. The optimal use of IVIg in the treatment of neurological disorders is therefore an important goal.

The Expert Consensus Statements on the Use of IVIg in Neurology have been developed to aid neurologists and clinicians in the use of intravenous immunoglobulin (IVIg) in neurological practice. The Second Edition Expert Consensus Statements on the Use of IVIg in Neurology can be downloaded (PDF: 700 KB).

You can also download a copy of the first edition of  The Expert Consensus Statements on the Use of IVIg in Neurology (PDF: 672 KB).

The Expert Consensus Statements on the use of IVIg in Neurology bring together in one publication:

  • a background of specific neurological disorders
  • available evidence in the use of IVIg in those disorders
  • an evidence based approach to the interpretation of all treatment studies
  • an expert summary statement of the place of IVIg therapy in the relevant condition with a clinical perspective from a group of experts in their field.

The second edition of the Expert Consensus Statements includes reviews on:

  • Guillain-Barré syndrome (GBS)
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) 
  • Multifocal motor neuropathy (MMN) 
  • Amyotrophic lateral sclerosis (ALS)
  • Myasthenia gravis 
  • Lambert - Eaton myasthenic syndrome (LEMS) 
  • Neuromyotonia (Isaacs’ syndrome) 
  • Dermatomyositis, polymyositis, inclusion body myositis 
  • Chronic fatigue syndrome 
  • Paraneoplastic neurological disorders 
  • Stiff - person syndrome 
  • Epilepsy 
  • Opsoclonus-myoclonus-ataxia
  • Acute disseminated encephalomyelitis
  • Brachial and lumbosacral plexopathies
  • IgM paraproteinemic neuropathies
  • Multiple sclerosis
  • Neuromyelitis optica.

The conditions chosen for review reflect the disorders commonly treated, or considered for treatment, with IVIg in neurological practice. In subsequent revisions of the publication each chapter will be revised to reflect any new information, and neurological disorders will be added.

The Expert Consensus Statements were ratified by the Scientific Committee of INDAPS in late October 2004 for the first edition and in June 2008 for the second edition.

A/Prof Andrew J. Kornberg
Chairman, Asia Pacific Immunoglobulins in Neurology Consensus Group
September 2008

© Asia Pacific Immunoglobulins in Neurology Consensus Group

Apart from any fair dealing for the use of private study, research, criticism, or review as permitted under the Copyright Act, no part of this book may be transmitted or reproduced in any form, electronic or mechanical, or by any information storage and retrieval system, without the written permission of the publishers.

This publication has been made possible by an undirected educational grant from CSL Biotherapies.

Waiver of Liability

The information contained in this document is intended to serve as a guideline only. Neither the contributing authors nor the Asia Pacific Immunoglobulins in Neurology Consensus Group shall be liable for any actions, claims, damages, costs or obligations that may arise from the inappropriate use or misuse of the material contained in the Consensus Statements.




DisclaimerPrivacy                                             INDAPS is sponsored by an unrestricted educational grant from CSL Biotherapies